11C-Choline PET/CT Patterns of Recurrence
| Parameter | Persistently elevated PSA (n = 69) | PSA relapse after RP (n = 108) | PSA relapse after RP plus radiotherapy (n = 79) | PSA relapse after radiotherapy (n = 30) |
| PSA level (ng/mL) | 2.1 (0.17–14.13) | 2.6 (0.19–89.91) | 2.8 (0.15–24.98) | 11.3 (0.75–50.15) |
| PET/CT positivity | 50 (72.5%) | 56 (52%) | 53 (67%) | 27 (90%) |
| T+ | 11 (16%) | 16 (15%) | 12 (15%) | 19 (63.5%) |
| N1 | 47 (68%) | 42 (39%) | 34 (43%) | 15 (50%) |
| M1a | 3 (4.5%) | 4 (3.5%) | 7 (9%) | 3 (10%) |
| M1b | 8 (11.5%) | 6 (5%) | 11 (14%) | 5 (17%) |
| M1c | 0 | 0 | 3 (4%) | 1 (3.5%) |
| T+N0M0 | 1 (1.5%) | 10 (9.5%) | 6 (7.5%) | 10 (33.5%) |
| T0N1M0 | 32 (46.5%) | 32 (29.5%) | 22 (28%) | 5 (16.5%) |
| T+N1M0 | 6 (8.5%) | 4 (3.5%) | 5 (6.5%) | 3 (10%) |
| T+N0M1 | 2 (3%) | 0 | 1 (1.5%) | 1 (3.5%) |
| T0N0M1 | 0 | 4 (4%) | 12 (15%) | 1 (3.5%) |
| T0N1M1 | 7 (10%) | 4 (3.5%) | 7 (9%) | 2 (6.5%) |
| T+N1M1 | 2 (3%) | 2 (2%) | 0 | 5 (16.5%) |
| Recurrence outside initial treatment field | 23 (33.5%) | 18 (17%) | 25 (32%) | 13 (43.5%) |